COSELA? received upgraded evidence-based medicine designation in the CSCO Guidelines for Small Cell Lung Cancer
点击量:297
On April 28, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharm...
Expanded Access Policy
点击量:410
Simcere pharma is a pharmaceutical company driven by innovative R&D, its mission is Providing To...
Simcere Zaiming will present six innovative researches at the 2024 AACR
点击量:1198
March 25 2024. Simcere Zaiming, the oncology subsidiary of Simcere Pharmaceutical Group Ltd, will pr...
Simcere Zaiming announces global FIH dosing of USP1 inhibitor in clinical trial
点击量:1015
On March 19, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharm...
Phase III Clinical Study of Daridorexant Achieved the Full Patient Enrollment in China
点击量:885
Phase III Clinical Study of Daridorexant Achieved the Full Patient Enrollment in ChinaOn March 15, 2...
New Drug Application Of Suvemcitug For Injection Has Been Accepted By the China National Medical Products Administration
On March 15, 2024, Simcere Zaiming Pharmaceutical Co. Ltd. (“Simcere Zaiming”), an innovative oncolo...
{转码主词}